Pre-Transplant Prediction of Acute Graft-versus-Host Disease Using the Gut Microbiome

Cells. 2022 Dec 16;11(24):4089. doi: 10.3390/cells11244089.

Abstract

Gut microbiota is thought to influence host responses to allogeneic hematopoietic stem cell transplantation (aHSCT). Recent evidence points to this post-transplant for acute graft-versus-host disease (aGvHD). We asked whether any such association might be found pre-transplant and conducted a metagenome-wide association study (MWAS) to explore. Microbial abundance profiles were estimated using ensembles of Kaiju, Kraken2, and DeepMicrobes calls followed by dimensionality reduction. The area under the curve (AUC) was used to evaluate classification of the samples (aGvHD vs. none) using an elastic net to test the relevance of metagenomic data. Clinical data included the underlying disease (leukemia vs. other hematological malignancies), recipient age, and sex. Among 172 aHSCT patients of whom 42 developed aGVHD post transplantation, a total of 181 pre-transplant tool samples were analyzed. The top performing model predicting risk of aGVHD included a reduced species profile (AUC = 0.672). Beta diversity (37% in Jaccard's Nestedness by mean fold change, p < 0.05) was lower in those developing aGvHD. Ten bacterial species including Prevotella and Eggerthella genera were consistently found to associate with aGvHD in indicator species analysis, as well as relief and impurity-based algorithms. The findings support the hypothesis on potential associations between gut microbiota and aGvHD based on a data-driven approach to MWAS. This highlights the need and relevance of routine stool collection for the discovery of novel biomarkers.

Keywords: aGvHD biomarkers; allo-HSCT; deep learning; human gut microbiome; metagenome-wide association; next generation sequencing; pre-transplant screening; taxonomic assignment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteria
  • Gastrointestinal Microbiome* / physiology
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Transplantation, Homologous

Grants and funding

This research was funded by the Danish National Research Foundation (grant DNRF 126) and the Danish Cancer Society (grant R167-A108665-17-S2), the Lundbeck Foundation (R218-2016-1482), the Novo Nordisk Foundation (NNF15OC0014158), and the Svend Anderson Foundation. IrsiCaixa is supported by the RED de SIDA RD16/0025/0041 and co-financed by the ISCIII and the European Regional Development Fund (ERDF), “Investing in your future”. This research was also supported by CIBER—Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU.